×
0 0 0 0 0 0.00172253875712216 0.000397508943951254 0.00172253875712216
Stockreport

Gilead's Vemlidy OK'd in Europe [Seeking Alpha]

GILEAD SCIENCES (GILD)  More Company Research Source: Seeking Alpha
Last gilead sciences earnings: 5/1 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
PDF As expected, the European Commission approves Gilead Sciences' (NASDAQ: GILD ) Vemlidy (tenofovir alafenamide, TAF) 25 mg, a once-daily tablet for the treatment of chronic hepatitis B virus (HBV) infection in adults and adolescents at least 12 years old who weigh at least 35 kg. The advisory committee CHMP adopted a positive opinion backing approval in November. Now read: Why We're Bullish On Gilead » [Read more]

IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS